Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Pediatrix Medical Group, Inc.NYSE: MD
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue growth accelerates
Q3 FY2026 cost of revenue of $436.16M rose 23.7% year over year, ahead of the +7.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Cost of revenue amounted to 75.3% of revenue in FY2025, down 2.1 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +23.7% holds above the trailing-twelve-month pace of +7.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.44B USD
- Year-over-year change
- -7.5%
- 4-year CAGR
- +0.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.44B | -7.5% |
| FY2024 | 2024-12-31 | 1.56B | -0.9% |
| FY2023 | 2023-12-31 | 1.57B | +4.5% |
| FY2022 | 2022-12-31 | 1.5B | +7.7% |
| FY2021 | 2021-12-31 | 1.4B | — |
Cost of Revenue vs competitors
How MD compares with its peers on the latest reported figures
- MD's LTM Sep 2026 cost of revenue of $1.53B is the 7th highest of the 11 companies compared; the peer median is $1.98B.
- Its year-over-year change of +7.1% is the 10th highest of 11, against a peer median of +18.9%.
- Cost of revenue amounts to 78.0% of revenue for MD, versus a peer median of 67.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.93B | +28.0% | -4.9% | 89.4% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $3.23B | +127.0% | -45.4% | 50.3% |
| LTM Mar 2026 | $3.2B | +61.8% | +45.1% | 90.7% | |
| LTM Sep 2026 | $2.84B | +0.3% | +7.6% | 46.6% | |
| LTM Sep 2026 | $2.14B | +252.6% | +200.9% | 62.7% | |
| LTM Oct 2026 | $1.82B | +19.3% | +9.7% | 67.9% | |
| LTM Sep 2026 | $1.53B | +7.1% | -1.4% | 78.0% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $1.15B | +7.6% | +17.3% | 78.4% |
| LTM Sep 2026 | $1.08B | +16.9% | +10.3% | 68.0% | |
| LTM Jun 2026 | $1.05B | +18.5% | +15.7% | 66.4% | |
| LTM Jun 2026 | $998.65M | +16.3% | +13.8% | 67.6% | |
| Peer median (excluding MD) | $1.98B | +18.9% | +12.1% | 67.8% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.91B | 1.97B | 1.99B | 2.01B | 1.91B |
| Cost of Revenue | 1.4B | 1.5B | 1.57B | 1.56B | 1.44B |
| Gross Profit | 513.24M | 467.03M | 421.57M | 454.34M | 471.88M |
| Gross Margin | 26.9% | 23.7% | 21.1% | 22.6% | 24.7% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 263.36M | 231.4M | 227.54M | 238.44M | 240.79M |
| Operating Expenses | 310.32M | 294.35M | 414.24M | 523.06M | 240.79M |
| Depreciation & Amortization | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| EBITDA | 236.1M | 156.7M | 29.89M | (28.37M) | 274.22M |
| EBITDA Margin | 12.4% | 7.9% | 1.5% | -1.4% | 14.3% |
| Operating Income | 202.92M | 172.69M | 7.32M | (68.71M) | 231.09M |
| Operating Margin | 10.6% | 8.8% | 0.4% | -3.4% | 12.1% |
| Interest Income | 0 | 0 | 0 | 0 | 19.05M |
| Interest Expense | 68.72M | 39.7M | 42.08M | 40.74M | 35.97M |
| Other Income / Expenses | (67.69M) | (91.32M) | (55.68M) | (32.63M) | (14.65M) |
| Income Before Tax | 135.23M | 81.37M | (48.36M) | (101.34M) | 216.43M |
| Pre-Tax Margin | 7.1% | 4.1% | -2.4% | -5.0% | 11.3% |
| Income Tax Expense | 27.24M | 18.81M | 12.05M | (2.27M) | 51.04M |
| Net Income | 130.96M | 66.34M | (60.41M) | (99.07M) | 165.39M |
| Net Margin | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% |
| EPS (Basic) | 1.52 | 0.80 | (0.73) | (1.19) | 1.94 |
| EPS (Diluted) | 1.52 | 0.79 | (0.73) | (1.19) | 1.94 |
| Weighted Avg Shares | 86.42M | 82.95M | 82.2M | 83.33M | 85.27M |
| Weighted Avg Shares (Diluted) | 86.42M | 84.12M | 82.2M | 83.33M | 85.27M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.